{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:23:17Z","timestamp":1757701397877},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.amjcard.2017.06.005","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T05:32:19Z","timestamp":1497591139000},"page":"792-796","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin \u2013 Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)"],"prefix":"10.1016","volume":"120","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naab","family":"Al-Saady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Melino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Zamoryakhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.06.005_bib0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.amjmed.2016.03.024","article-title":"Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials","volume":"129","author":"Proietti","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0025","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ehjcvp\/pvv012","article-title":"Simple decision making between a Vitamin K antagonist and non-Vitamin K antagonist oral anticoagulant (NOACs): using the SAMe-TT2R2 Score","volume":"1","author":"Proietti","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1160\/TH15-02-0169","article-title":"Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists","volume":"114","author":"Ruiz-Ortiz","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0040","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1160\/TH15-06-0518","article-title":"The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?","volume":"114","author":"Fauchier","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation","volume":"146","author":"Lip","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2015.02.009","article-title":"A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study","volume":"169","author":"Lip","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0065","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ebiom.2016.04.013","article-title":"Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF Trials","volume":"8","author":"Proietti","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0080","doi-asserted-by":"crossref","first-page":"e74037","DOI":"10.1371\/journal.pone.0074037","article-title":"Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial","volume":"8","author":"Clarkesmith","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/europace\/euv191","article-title":"European Heart Rhythm Association\/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society","volume":"18","author":"Lip","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.08.030","article-title":"The sex, age, medical history, treatment, tobacco use, race risk (SAMe TT2R2) score predicts warfarin control in a Singaporean population","volume":"26","author":"Bernaitis","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1378\/chest.13-1897","article-title":"SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic","volume":"145","author":"Skov","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14779072.2016.1116941","article-title":"The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation","volume":"14","author":"Esteve-Pastor","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2017.06.005_bib0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.2016.9356","article-title":"Stability of international normalized ratios in patients taking long-term warfarin therapy","volume":"316","author":"Pokorney","year":"2016","journal-title":"JAMA"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917309578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917309578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T01:30:33Z","timestamp":1569461433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917309578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0002914917309578"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.005","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin\u2013Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}